Priority for Pediatric Cures Act

The Priority for Pediatric Cures Act permanently extends the authority to award priority review vouchers for drugs and biologics that treat rare pediatric diseases. By amending the Federal Food, Drug, and Cosmetic Act, the bill removes a specific expiration provision that would otherwise limit this incentive program. This change ensures that pharmaceutical companies can continue to receive expedited FDA review in exchange for developing treatments for children with rare conditions.